
Savolitinib/Osimertinib Yields Durable Responses in EGFR-Mutated, MET+ NSCLC
Combination therapy with the MET tyrosine kinase inhibitor savolitinib plus osimertinib (Tagrisso) led to high and durable response rates and was well tolerated for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) and …